TY - JOUR
T1 - Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients with BRAF V600-Mutant Metastatic Non-Small-Cell Lung Cancer
AU - Riely, Gregory J.
AU - Smit, Egbert F.
AU - Ahn, Myung Ju
AU - Felip, Enriqueta
AU - Ramalingam, Suresh S.
AU - Tsao, Anne
AU - Johnson, Melissa
AU - Gelsomino, Francesco
AU - Esper, Raymond
AU - Nadal, Ernest
AU - Offin, Michael
AU - Provencio, Mariano
AU - Clarke, Jeffrey
AU - Hussain, Maen
AU - Otterson, Gregory A.
AU - Dagogo-Jack, Ibiayi
AU - Goldman, Jonathan W.
AU - Morgensztern, Daniel
AU - Alcasid, Ann
AU - Usari, Tiziana
AU - Wissel, Paul
AU - Wilner, Keith
AU - Pathan, Nuzhat
AU - Tonkovyd, Svitlana
AU - Johnson, Bruce E.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2023/7/20
Y1 - 2023/7/20
N2 - PURPOSEThe combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAFV600E/K-mutant metastatic melanoma. We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC).METHODSIn this ongoing, open-label, single-arm, phase II study, patients with BRAFV600E-mutant metastatic NSCLC received oral encorafenib 450 mg once daily plus binimetinib 45 mg twice daily in 28-day cycles. The primary end point was confirmed objective response rate (ORR) by independent radiology review (IRR). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival, time to response, and safety.RESULTSAt data cutoff, 98 patients (59 treatment-naïve and 39 previously treated) with BRAFV600E-mutant metastatic NSCLC received encorafenib plus binimetinib. Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib. ORR by IRR was 75% (95% CI, 62 to 85) in treatment-naïve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively. DCR after 24 weeks was 64% in treatment-naïve and 41% in previously treated patients. Median PFS was NE (95% CI, 15.7 to NE) in treatment-naïve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients. The most frequent treatment-related adverse events (TRAEs) were nausea (50%), diarrhea (43%), and fatigue (32%). TRAEs led to dose reductions in 24 (24%) and permanent discontinuation of encorafenib plus binimetinib in 15 (15%) patients. One grade 5 TRAE of intracranial hemorrhage was reported. Interactive visualization of the data presented in this article is available at the PHAROS dashboard (https://clinical-trials.dimensions.ai/pharos/).CONCLUSIONFor patients with treatment-naïve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma.
AB - PURPOSEThe combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAFV600E/K-mutant metastatic melanoma. We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC).METHODSIn this ongoing, open-label, single-arm, phase II study, patients with BRAFV600E-mutant metastatic NSCLC received oral encorafenib 450 mg once daily plus binimetinib 45 mg twice daily in 28-day cycles. The primary end point was confirmed objective response rate (ORR) by independent radiology review (IRR). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival, time to response, and safety.RESULTSAt data cutoff, 98 patients (59 treatment-naïve and 39 previously treated) with BRAFV600E-mutant metastatic NSCLC received encorafenib plus binimetinib. Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib. ORR by IRR was 75% (95% CI, 62 to 85) in treatment-naïve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively. DCR after 24 weeks was 64% in treatment-naïve and 41% in previously treated patients. Median PFS was NE (95% CI, 15.7 to NE) in treatment-naïve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients. The most frequent treatment-related adverse events (TRAEs) were nausea (50%), diarrhea (43%), and fatigue (32%). TRAEs led to dose reductions in 24 (24%) and permanent discontinuation of encorafenib plus binimetinib in 15 (15%) patients. One grade 5 TRAE of intracranial hemorrhage was reported. Interactive visualization of the data presented in this article is available at the PHAROS dashboard (https://clinical-trials.dimensions.ai/pharos/).CONCLUSIONFor patients with treatment-naïve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma.
UR - http://www.scopus.com/inward/record.url?scp=85165222446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165222446&partnerID=8YFLogxK
U2 - 10.1200/JCO.23.00774
DO - 10.1200/JCO.23.00774
M3 - Article
C2 - 37270692
AN - SCOPUS:85165222446
SN - 0732-183X
VL - 41
SP - 3700
EP - 3711
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 21
ER -